Related Articles
Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report
Association of human epidermal growth factor receptor 2 status with ipsilateral breast tumor recurrence and resistance to endocrine therapy
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer (Review)
Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions